NGP 555

Drug Profile

NGP 555

Alternative Names: NGP-555; NGX-555

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TorreyPines Therapeutics Inc
  • Developer NeuroGenetic Pharmaceuticals
  • Class Amines; Antidementias; Fluorine compounds; Imidazoles; Small molecules; Thiazoles
  • Mechanism of Action Amyloid precursor protein secretase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 09 Jan 2017 NeuroGenetic Pharmaceuticals completes a phase Ib trial in healthy volunteers in USA
  • 01 Jan 2016 NeuroGenetic Pharmaceuticals initiates enrolment in a phase Ib trial in healthy volunteers in USA (NCT02537938)
  • 10 Nov 2015 NeuroGenetic Pharmaceuticals completes a phase Ia trial in Alzheimer’s disease (In volunteers) in USA (NCT02534480,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top